OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Sees Large Drop in Short Interest

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO – Get Free Report) saw a large decrease in short interest in October. As of October 30th, there was short interest totaling 45,609 shares, a decrease of 40.5% from the October 15th total of 76,652 shares. Based on an average daily volume of 54,910 shares, the short-interest ratio is presently 0.8 days. Approximately 0.1% of the company’s shares are sold short.

Institutional Trading of OKYO Pharma

A hedge fund recently bought a new stake in OKYO Pharma stock. Opaleye Management Inc. purchased a new position in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO – Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 375,204 shares of the company’s stock, valued at approximately $563,000. Opaleye Management Inc. owned 0.71% of OKYO Pharma at the end of the most recent quarter. 2.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

OKYO has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of OKYO Pharma in a research note on Wednesday, October 7th. Weiss Ratings downgraded shares of OKYO Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.67.

Check Out Our Latest Stock Analysis on OKYO

OKYO Pharma Price Performance

OKYO Pharma stock opened at $1.18 on Tuesday. OKYO Pharma has a 52 week low of $1.15 and a 52 week high of $3.20. The company’s 50 day moving average price is $1.40 and its two-hundred day moving average price is $1.57.

About OKYO Pharma

(Get Free Report)

OKYO Pharma Limited is a clinical-stage biopharmaceutical company developing treatments for inflammatory eye diseases and ocular pain. Its research focuses on therapies intended to reduce inflammation and improve symptoms affecting the eye. The company’s lead candidate, urcosimod (OK-101), is a topical eye-drop treatment being developed for dry eye disease. It is designed to act on ChemR23, a receptor involved in regulating inflammation. OKYO has also investigated the candidate’s potential for treating neuropathic corneal pain.

See Also

Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.